Top Message

We aspire to develop the world’s first iPS cell-derived cardiomyocyte sheet at as early stage as possible to deliver it to patients with severe heart failure.


Cuorips Inc. is a startup established in March 2017 based on the research achievements of Professor Sawa and his group of the Department of Cardiovascular Surgery, Osaka University. Its aim is to develop and commercialize iPS cell-derived cardiomyocyte sheets.
The population of patients with heart failure is extremely large, and is considered to reach 1.6 million people in Japan. This situation is similar to a pandemic outbreak and it is expected that this population will further increase.

Our mission is to help people live healthy and joyfully by utilizing new and reliable technologies and achieving more patient-oriented healthcare.

As the first challenge toward this goal, we will establish efficient technology for the production of an iPS cell-derived cardiomyocyte sheet, and aim to subsequently achieve authorization of the sheet.

President Hidemi Masumura, Ph.D.